SS
PTGX icon

SBI Securities’s Protagonist Therapeutics PTGX Stock Holding History

SBI Securities’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.81K Buy
80
+10
+14% +$1.04K ﹤0.01% 1848
2026
Q1 		$7.38K Hold
70
– – ﹤0.01% 1869
2025
Q4 		$6.11K Buy
+70
New +$5.73K ﹤0.01% 1944

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

SBI Securities's PTGX Position: Q2 2026 in Review

SBI Securities increased its Protagonist Therapeutics (PTGX) stake by 14% in Q2 2026, buying an estimated $1.04K and bringing the position to 80 shares worth $9.81K. The position accounts for ﹤0.01% of the portfolio, ranked #1848.

SBI Securities first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • SBI Securities held 80 shares of Protagonist Therapeutics worth $9.81K as of Q2 2026.
  • SBI Securities bought 10 Protagonist Therapeutics shares in Q2 2026, an estimated $1.04K.
  • Protagonist Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1848 holding.
  • SBI Securities first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.